These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38433564)

  • 1. Supramolecular Lipid Nanoparticles Based on Host-Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy.
    Qi S; Zhang X; Yu X; Jin L; Yang K; Wang Y; Feng Y; Lei J; Mao Z; Yu G
    Adv Mater; 2024 Jun; 36(23):e2311574. PubMed ID: 38433564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-Responsive β-Glucans-Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy.
    Luo PK; Ho HM; Chiang MC; Chu LA; Chuang YH; Lyu PC; Hu IC; Chang WA; Peng SY; Jayakumar J; Chen HL; Huang MH; Sung HW
    Adv Mater; 2024 Aug; 36(33):e2404830. PubMed ID: 38895941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
    Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
    Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Mannosylated Lipid Nanoparticles for mRNA Cancer Vaccine with High Antigen Presentation Efficiency and Immunomodulatory Capability.
    Lei J; Qi S; Yu X; Gao X; Yang K; Zhang X; Cheng M; Bai B; Feng Y; Lu M; Wang Y; Li H; Yu G
    Angew Chem Int Ed Engl; 2024 Mar; 63(13):e202318515. PubMed ID: 38320193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
    Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
    J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.
    Oberli MA; Reichmuth AM; Dorkin JR; Mitchell MJ; Fenton OS; Jaklenec A; Anderson DG; Langer R; Blankschtein D
    Nano Lett; 2017 Mar; 17(3):1326-1335. PubMed ID: 28273716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine.
    Fan YN; Li M; Luo YL; Chen Q; Wang L; Zhang HB; Shen S; Gu Z; Wang J
    Biomater Sci; 2018 Nov; 6(11):3009-3018. PubMed ID: 30264063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
    Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
    Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy.
    Zhang H; Xia X
    Hum Vaccin Immunother; 2021 Sep; 17(9):2995-2998. PubMed ID: 33945399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity.
    Xu Z; Xiao ZX; Wang J; Qiu HW; Cao F; Zhang SQ; Xu YD; Lei HQ; Xia H; He YR; Zha GF; Pang J
    Oncoimmunology; 2024; 13(1):2373526. PubMed ID: 38948931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
    Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
    ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
    van den Ancker W; van Luijn MM; Ruben JM; Westers TM; Bontkes HJ; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
    Cancer Immunol Immunother; 2011 Jan; 60(1):37-47. PubMed ID: 20859626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells.
    Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V
    J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine.
    Tateshita N; Miura N; Tanaka H; Masuda T; Ohtsuki S; Tange K; Nakai Y; Yoshioka H; Akita H
    J Control Release; 2019 Sep; 310():36-46. PubMed ID: 31386869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
    Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
    Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Adjuvant-Loaded Peptide Antigen Self-Assembly Potentiates Dendritic Cell-Mediated Tumor Immunotherapy.
    Kim J; Kang S; Kim J; Yong SB; Lahiji SF; Kim YH
    Adv Sci (Weinh); 2024 Sep; 11(36):e2403663. PubMed ID: 39073756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CO-DELIVERY of glutamic acid-extended peptide antigen and imidazoquinoline TLR7/8 agonist via ionizable lipid nanoparticles induces protective anti-tumor immunity.
    Ye T; Zhong Z; Cappellesso F; Deswarte K; Chen Y; Lauwers H; De Lombaerde E; Gontsarik M; Lienenklaus S; Van Lysebetten D; Sanders NN; Lambrecht BN; De Koker S; Laoui D; De Geest BG
    Biomaterials; 2024 Dec; 311():122693. PubMed ID: 38996672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.